 By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. NASDAQ:ORMP, a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, presented preliminary data findings from its NASH study at the American Diabetes Association Scientific Session 2020 this week. The company announced that its NASH study has shown ORMD-0801 to be 